Retrospective Cohort Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Feb 21, 2020; 26(7): 740-748
Published online Feb 21, 2020. doi: 10.3748/wjg.v26.i7.740
Table 1 Baseline characteristics and clinical information of the biliary spontaneous dislodgement spiral stent and nasobiliary groups, n (%)
BSDSS group (n = 21)Nasobiliary tube group (n = 28)P value
Age, mean ± SD, yr64 ± 1667 ± 190.5725
Sex, male/female11/1013/150.6806
Diagnosis0.9517
Biliary colic6 (28.6)10 (35.7)
Obstructive jaundice7 (33.3)8 (28.6)
Acute cholangitis16 (28.6)7 (25.0)
Acute pancreatitis12 (9.5)3 (10.7)
Comorbidity210 (47.6)18 (64.3)0.2436
Gallbladder status0.4107
Post cholecystectomy12 (57.1)13 (46.4)
Cholecystectomy after ERCP2 (9.5)1 (3.6)
Gallbladder stones in situ5 (23.8)6 (21.4)
No gallbladder stones2 (9.5)8 (28.6)
Previous EST2 (9.5)6 (21.4)0.4387
Periampullary diverticulum11 (52.4)12 (42.9)0.5096
Maximum CBD diameter, median (IQR), mm13 (12-16)15 (13-15)0.2148
Maximum stone diameter, median (IQR), mm13 (11-16)12 (12-15)0.5818
Minimum stone diameter, median (IQR), mm10 (9-12)12 (10-12)0.7618
Stones number, < 3/≥ 314/725/30.0766
ERCP modalities for stone removal0.5957
ML31 (4.8)4 (14.3)
EST + ML3 (14.3)6 (21.4)
EPBD + ML31 (4.8)2 (7.1)
EST + EPBD + ML16 (76.2)16 (57.1)
Residual debris41 (4.8)5 (17.9)0.2197
Table 2 Clinical outcomes of the biliary spontaneous dislodgement spiral stent and nasobiliary tube groups, n (%)
BSDSS group (n = 21)Nasobiliary tube group (n = 28)P value
Technical success21 (100)28 (100)-
Overall post-ERCP adverse events1 (4.8)5 (17.9)0.2194
Cholangitis0 (0)0 (0)-
Pancreatitis11 (4.8)1 (3.6)1.0004
CBD stone recurrence0 (0)1 (3.6)1.0004
Other events20 (0)3 (10.7)0.2504
Follow-up duration, median (IQR), mo19 (17-22)18 (15-21)0.3655
Drainage time3, median (IQR), d3 (3-5)4 (2-5)0.9345
Postoperative stay, median (IQR), d4 (3-6)5 (3-7)0.2235